Sirolimus to help prevent loss of daily function
Treatments studied
This Phase 2 trial studies whether sirolimus can slow or prevent functional decline (more difficulty with daily activities) in older adults. You may be considered if you’re in the right age range and have no major heart, lung, liver, kidney, or recent bleeding/clotting problems.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be age 65 to 80 (adult)
- Be postmenopausal, or have had surgical sterilization
- Have kidney function strong enough (creatinine clearance at least 30 mL/min)
- Do not have chronic liver disease
- Be free of certain recent problems (no major surgery/major injury, major bleeding/ulcers, or clot/stroke in the last 3–12 months)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called sirolimus to see if it can help older adults stay healthy and independent. The trial is looking for people aged 65 and older who live at home and do not have serious memory problems or major health conditions like kidney or liver disease.
This trial tests two FDA-approved drugs, rapamycin and everolimus, to see if they can improve immune function in healthy older adults. You may join if you are generally healthy, live independently, and are between 65 and 90 years old.
This early-phase study tests how a medicine called rapalog affects the body in generally healthy middle-aged adults. It may help researchers understand safety and dosing, but it’s not meant to treat an existing disease.
This trial tests whether sirolimus, a medication usually used to prevent organ transplant rejection, can help reduce lupus disease activity. If you have active lupus that isn't severe in your kidneys or brain, this could be a new treatment option.
This study tests whether sirolimus (an immune-calming drug) is safe and helpful for people with antiphospholipid syndrome (APS), a condition that raises the risk of blood clots. If you join, you'll get either sirolimus or a placebo alongside your usual treatment, to see if it reduces clotting problems.
This study tests whether sirolimus, a medication that may help the body clear damaged cells, can lower Alzheimer's risk in women with the ApoE4 gene variant. It is an early-stage trial that looks at safety and how the drug affects certain blood markers.
Hear when a new Aging trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.